developing Game-Changing molecular imaging technologies

Through its two wholly owned subsidiaries, Serac Life Sciences is developing two late-stage molecular imaging technologies to help physicians deliver personalised medicine to more patients.  

developing Game-Changing molecular imaging technologies

Through its two wholly owned subsidiaries, Serac Life Sciences is developing two late-stage molecular imaging technologies to help physicians deliver personalised medicine to more patients.  

Our goal is to bring better care & quality of life to patients wherever they are

Images courtesy of Dr Toby Garrood, Guy’s Hospital, London

99mTc-maraciclatide - A novel imaging agent under investigation for inflammatory arthritis and endometriosis

Serac Healthcare is a clinical radiopharmaceutical company with deep expertise in discovering, developing and commercialising innovative molecular imaging technologies. Its goal is to bring to market effective tools to accelerate diagnosis and to deliver earlier and more effective treatment decisions for patients.

Its radio-labelled imaging agent, 99mTc-maraciclatide, is being developed to underpin personalised medicine primarily in the fields of endometriosis and inflammatory arthritis.

99mTc-maraciclatide binds to the αvβ3 integrin which is crucial to the development of new blood vessels, a key feature of both conditions.

Clinical trials with world-leading academic partners are underway in both these indications.

99mTc-maraciclatide is for investigational use only and is not approved by the FDA or UK and European regulatory authorities.

Seracam® - A revolutionary high resolution hybrid gamma-optical camera for point-of-care imaging

Serac Imaging Systems is a medtech company and developer of Seracam.

Seracam incorporates cutting-edge technology into a miniaturised, cost-effective, high resolution gamma camera with real time optical video image fusion. It has been designed as a highly versatile and compact alternative to traditional fixed nuclear medicine cameras, to enable molecular imaging procedures at the patient bedside, and also improve workflow in the nuclear medicine department.

Seracam is currently being evaluated in a number of clinical settings.

Seracam is for investigational use only and has not been cleared or approved by the FDA or UK and European regulatory authorities.

Women worldwide affected by endometriosis
0 m
People worldwide live with rheumatoid arthritis
0 m
Standard nuclear medicine procedures
0 +
Average time to diagnose endometriosis
0 yrs
Cost/yr of rheumatoid arthritis to the US economy
$ 0 bn
Nuclear medicine facilities worldwide
0

Investment Opportunities

Serac Life Sciences is a privately owned holding company for Serac Healthcare Ltd and Serac Imaging Systems Ltd. We are always ready to talk to investors who match our ambitions and can help us excel. If you would like to discuss investment opportunities, please do get in touch.

Our Board

Discover more about the team behind Serac Life Sciences

Latest News

Create an account to access this functionality.
Discover the advantages